MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00535-013-0872-4

Медицинская библиотека · Journal of gastroenterology · 2013

The 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet's disease: indication of anti-TNFα monoclonal antibodies.

Hisamatsu Tadakazu, Ueno Fumiaki, Matsumoto Takayuki, Kobayashi Kiyonori, Koganei Kazutaka, Kunisaki Reiko, Hirai Fumihito, Nagahori Masakazu, Matsushita Mitsunobu, Kobayashi Kenji, Kishimoto Mitsumasa, Takeno Mitsuhiro, Tanaka Masanori, Inoue Nagamu, Hibi Toshifumi

Consensus StatementСтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

Clinical evidence regarding intestinal Behçet's disease (BD) management is lacking and intestinal lesions are a poor prognostic factor. In 2007, the Japan consensus statement for diagnosis and management of intestinal BD was developed. Recently, the efficacy of anti-tumor necrosis factor (TNF)α monoclonal antibodies (mAbs), and infliximab (IFX) was reported and adalimumab (ADA) was approved for intestinal BD in Japan. This study renewed consensus-based practice guidelines for diagnosis and treatment of intestinal BD focusing on the indication of anti-TNFα mAbs.

METHODS

An expert panel of Japanese gastroenterology and rheumatology specialists was involved. Clinical statements for ratings were extracted from the literature, a professional group survey, and by an expert panel discussion, which rated clinical statements on a nine-point scale. After the first round of ratings, a panelist meeting discussed areas of disagreement and clarified areas of uncertainty. The list of clinical statements was revised after the panelist meeting and a second round of ratings was conducted.

RESULTS

Fifteen relevant articles were selected. Based on the first edition consensus statement, improved clinical statements regarding indications for anti-TNFα mAbs use were developed. After a two-round modified Delphi approach, the second edition of consensus statements was finalized.

CONCLUSIONS

In addition to standard therapies in the first edition, anti-TNFα mAbs (ADA and IFX) should be considered as a standard therapy for intestinal BD. Colchicines, thalidomide, other pharmacological therapy, endoscopic therapy, and leukocytapheresis were deemed experimental therapies.

Для цитирования: Hisamatsu Tadakazu, Ueno Fumiaki, Matsumoto Takayuki, Kobayashi Kiyonori, Koganei Kazutaka, Kunisaki Reiko, Hirai Fumihito, Nagahori Masakazu, Matsushita Mitsunobu, Kobayashi Kenji, Kishimoto Mitsumasa, Takeno Mitsuhiro, Tanaka Masanori, Inoue Nagamu, Hibi Toshifumi. The 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet's disease: indication of anti-TNFα monoclonal antibodies.. Journal of gastroenterology. 2013. DOI: 10.1007/s00535-013-0872-4.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.